Impact of the Polymorphism rs9264942 near the HLA-C Gene on HIV-1 DNA Reservoirs in Asymptomatic Chronically Infected Patients Initiating Antiviral Therapy

Table 3

Frequencies of the individuals carrying the protective allele rs9264942–35 C (genotypes CC + CT) versus noncarriers of this allele (genotype TT). HIV-1 RNA and HIV-1 DNA levels are shown in the patients naïve for antiretroviral therapy (pre-ART), one month (1 m) post-ART, and at the end of the study (follow-up: 36 months).

rs9264942 (T > C); −35 C allele (genotypes)		Frequency (%)	HIV-1 RNA median (min–max)			HIV-1 DNA median (min–max)
			Pre-ART	1 m post-ART	End of study	Pre-ART	1 m post-ART	End of study
Total	Noncarriers (TT)	54 (29.5%)	24,976 (200–460,000)	200 (200–60,000)	3600 (200–56,543)	927,5 (250–32,560)	1080 (250–10,645)	250 (250–2570)
	Carriers (CT + CC)	129 (70.5%)	10,100 (200–274,500)	200 (200–25,000)	1730 (200–132,000)	500 (250–17,425)	425 (250–18,855)	250 (250–15,920)
				N.S.	N.S.			N.S.

Median and minimum–maximum values of viremia and cellular-associated viral loads are indicated for the respective genotypes, HIV-1 RNA in copies/mL, and HIV-1 DNA in copies/10⁶ PBMCs. The values are for median comparisons; N.S.: not significant.